ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD - News), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

• Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No.: A106, "A Phase 1 study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)," Halls C-D, 2nd floor.
• Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No.: A156, "Mechanisms of resistance to Aurora kinase B inhibitors in leukemia: development and characterization of in vitro models," Halls C-D, 2nd floor.
• Poster Session: Wednesday, November 18, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No: C75, "A novel multi-targeted Aurora A and VEGFR2 kinase inhibitor, ENMD-2076, demonstrates synergistic antiproliferative and proapoptotic effects in combination with chemotherapy and trastuzumab in breast cancer cell lines," Halls C-D, 2nd floor.

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers, multiple myeloma, and leukemia. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem® in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.